HIV research findings made possible by a test developed at CU School of Pharmacy

July 28, 2014

An influential new test, discovered and developed in the Colorado Antiviral Pharmacology Laboratory at the CU School of Pharmacy, helps monitor the effectiveness of the HIV prevention drug called Truvada (a combination of tenofovir/emtricitabine), which is taken once daily to prevent HIV infection.

A study presented during the AIDS 2014 Conference and published in Lancet Infectious Diseases on the efficacy and safety of prophylactic use of Truvada to protect against HIV infection relied on a test developed at the school. The test measures the amount of tenofovir-diphosphate (a metabolite of tenofovir) in , using a dried blood spot. Because of a long half-life, high amounts of the metabolite in the dried blood spot correspond with consistent dosing of Truvada and low amounts correspond with inconsistent dosing. The new test was used in the iPrEx open label extension study (iPrEx OLE) to estimate patterns of tablet use during the study. The new test showed a continuous gradient of increasing efficacy (fewer HIV infections) with increasing drug concentrations. Dr. Peter Anderson, whose laboratory developed the test, said, "Participants in the study who had tablet use consistent with 4 or more tablets per week, as determined by the new test, had no HIV infections (estimated 100% efficacy)."

The US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recently issued guidelines recommending the use of antiretroviral medicines as an additional method of preventing HIV infection. "Findings from iPrEX OLE are particularly important in relation to emerging guidelines recommending widespread use of PrEP," said Protocol Chair Robert Grant, MD, PGH of the Gladstone Institutes, the University of California at San Francisco and the San Francisco AIDS Foundation.

Explore further: NIH-funded analysis estimates effective PrEP dosing

Related Stories

NIH-funded analysis estimates effective PrEP dosing

September 13, 2012

Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP. The level ...

HIV pills show more promise to prevent infection

July 22, 2014

There is more good news about HIV treatment pills used to prevent infection in people at high risk of getting the AIDS virus: Follow-up from a landmark study that proved the drug works now shows that it does not encourage ...

Recommended for you

Scientists jump hurdle in HIV vaccine design

May 26, 2017

Scientists at The Scripps Research Institute (TSRI) have made another important advance in HIV vaccine design. The development was possible thanks to previous studies at TSRI showing the structures of a protein on HIV's surface, ...

Study reveals how HIV virus destroys lung tissue

May 17, 2017

Up to 30 percent of HIV patients who are appropriately treated with antiretroviral therapies develop the chronic lung disease emphysema. New research from Weill Cornell Medicine investigators has uncovered a mechanism that ...

Researchers take an important step toward an HIV vaccine

May 17, 2017

Researchers from the University of Copenhagen have developed a strategy that can revolutionize vaccine design. The new strategy is used to develop vaccines that can prevent HIV infection and the development of AIDS.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.